Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Blood Cancer Journal

Volumn 4, Issue 11, 2014, Pages

  Dimopoulos, M A ^a   Swern, A S ^b   Li, J S ^b   Hussein, M ^b   Weiss, L ^b   Nagarwala, Y ^b   Baz, R ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CELGENE CORPORATION   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; LENALIDOMIDE; PLACEBO; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE;

EID: 84927949819     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.77     Document Type: Article

References (25)

1. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Multiple Myeloma (009) study investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
2. Dimopoulos MA, Spencer A, Attal M, Prince HM, Harousseau JC, Dmoszynska A et al. Multiple Myeloma (010) study investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
3. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
4. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82: 426-432.
5. Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011; 25: 1620-1626.
6. Harousseau J-L, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010; 95: 1738-1744.
7. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo M-L et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011; 11: 38-43.
8. Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N et al. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia 2013; 27: 2422-2424.
9. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
10. National Cancer Institute's Common Toxicity Criteria. Version 2.0 [Internet] 1999 [updated 30 April 1999]. Available from: http://www.eortc.be/services/doc/ctc/ ctcv20-4-30-992.pdf.
11. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119: 2764-2767.
12. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
13. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch AR, Hulin C et al. Initial phase 3 results of the FIRST (frontline investigation of lenalidomide+dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (pts) ineligible for stem cell transplantation (SCT). Blood 2013; 122 (abstract 2).
14. Palumbo A, Magarotto V, Bringhen S, Offidani M, Pietrantuono G, Liberati AM et al. A randomized phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs lenalidomide plus dexamethasone (Rd) in elderly newly diagnosed multiple myeloma patients. Blood 2013; 122 (abstract 536).
15. Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011; 25: 749-760.
16. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010; 24: 1769-1778.
17. Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 2013; 119: 3680-3686.
18. Oehrlein K, Rendl C, Hahn-Ast C, Kanz L, Weisel KC. Lenalidomide in relapsed and refractory multiple myeloma disease: Feasibility and benefits of long-term treatment. Blood 2012; 120 (abstract 4069).
19. Baz R, Dimopoulos M, Richardson P, Yu Z, Hussein M, Chanan-Khan A. Lenalidomide-based therapy leads to improvement of humoral immunity in relapsed or refractory multiple myeloma patients who respond to the therapy. Haematologica 2009; 94: 159 (abstract 0395).
20. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579.
21. Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M et al. How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 5-11.
22. Mateos M-V, Garcia-Sanz R, Colado E, Olazábal J, San-Miguel J. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008; 140: 324-326.
23. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
24. Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88: 67-71.
25. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF et al. SEER Cancer Statistics Review, 1975-2010 [updated 2013 Jun 14]. 2012, National Cancer Institute: Bethesda, MD, USA. Available at: http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.